November 7, 2019

Alzheimer’s Disease Clinical Trials in the Down Syndrome Population Planning Meeting Agenda

NIH INCLUDE Project: Alzheimer’s Disease Clinical Trials in the Down Syndrome Population Planning Meeting
November 7, 2018
6710B Rockledge Drive, Rooms 1425 and 1427
Bethesda, MD

9:00 a.m.
NIH Welcome and Introductions

9:15 a.m.
Overview of the NIH INCLUDE Project
Anna Mazzucco, NIH Office of the Director

9:30 a.m.
Overview of DS-Connect® and the Down syndrome Consortium
Melissa Parisi, NICHD

9:40 a.m.
NIH-Supported Alzheimer’s Disease and Down Syndrome Clinical Trial Resources:

• Alzheimer’s Biomarkers Consortium – Down Syndrome (ABC-DS)—Ben Handen, University of Pittsburgh
• Alzheimer’s Clinical Trial Consortium – Michael Rafii and Paul Aisen, University of Southern California
• National Alzheimer’s Coordinating Center – Nina Silverberg, National Institute on Aging

10:45 a.m.
BREAK

11:00 a.m.
Down Syndrome Professional and Advocacy Group Resources and Initiatives

• Alzheimer’s Association
• American Academy of Developmental Medicine and Dentistry – National Task Group on Intellectual Disabilities and Dementia Practices
• The Down Syndrome Medical Interest Group – USA (DSMIG-USA)
• Global Down Syndrome Foundation (GDSF)
• LuMind Research Down Syndrome Foundation
• T21 Research Society

12:00 p.m.
LUNCH

1:00 p.m.
Lessons from NIH-Supported AD Clinical Trials in Down Syndrome

• Vitamin E in Aging Persons with Down Syndrome Trial, the International, Down Syndrome and Alzheimer’s Disease Consortium – Paul Aisen, University of Southern California
• 3 Star Study (ACI-24) – Michael Rafii, University of Southern California

1:50 p.m.
Lessons from NIH-supported Clinical Trial Initiatives in Other Genetically At-Risk Populations

• Alzheimer’s Prevention Initiative (API) – Eric Reiman, Banner Alzheimer’s Institute
• Dominantly Inherited Alzheimer’s Network – Therapeutic Unit (DIAN-TU) – Eric McDade, Washington University

2:30 p.m.
Lessons from Other Clinical Trials in Down Syndrome

• CLEMATIS Trial of RG1662 (basmisanil) for memory and adaptive function – Sarah Hart, Duke University
• Scyllo-Inositol trial – Michael Rafii, University of Southern California

3:10 p.m.
Research Challenges: Open Discussion

4:25 p.m.
Next Steps: DS/AD Workshop in March 2019

4:45p.m.
ADJOURN